Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
La Jolla Institute for Immunology, La Jolla, CA, USA.
Nat Metab. 2024 Apr;6(4):617-638. doi: 10.1038/s42255-024-01015-w. Epub 2024 Mar 26.
Accumulating evidence over the past decades has revealed an intricate relationship between dysregulation of cellular metabolism and the progression of atherosclerotic cardiovascular disease. However, an integrated understanding of dysregulated cellular metabolism in atherosclerotic cardiovascular disease and its potential value as a therapeutic target is missing. In this Review, we (1) summarize recent advances concerning the role of metabolic dysregulation during atherosclerosis progression in lesional cells, including endothelial cells, vascular smooth muscle cells, macrophages and T cells; (2) explore the complexity of metabolic cross-talk between these lesional cells; (3) highlight emerging technologies that promise to illuminate unknown aspects of metabolism in atherosclerosis; and (4) suggest strategies for targeting these underexplored metabolic alterations to mitigate atherosclerosis progression and stabilize rupture-prone atheromas with a potential new generation of cardiovascular therapeutics.
在过去几十年中,越来越多的证据表明,细胞代谢失调与动脉粥样硬化性心血管疾病的进展之间存在着复杂的关系。然而,人们对动脉粥样硬化性心血管疾病中细胞代谢失调的综合理解及其作为治疗靶点的潜在价值仍存在缺失。在这篇综述中,我们:(1)总结了近年来关于在病变细胞(包括内皮细胞、血管平滑肌细胞、巨噬细胞和 T 细胞)中,代谢失调在动脉粥样硬化进展过程中所起作用的最新进展;(2)探讨了这些病变细胞之间代谢交叉对话的复杂性;(3)强调了有望阐明动脉粥样硬化中代谢未知方面的新兴技术;(4)提出了针对这些尚未充分探索的代谢改变的策略,以减轻动脉粥样硬化的进展,并稳定易破裂的动脉粥样瘤,为心血管治疗带来新一代的潜在可能。